ArticleEClinicalMedicine2025

Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial.

Zhi Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.